Medical Cannabis Authorization in Patients With Cancer in the Prelegalization Era: A Population-Based Study

Karim, Safiya; Cheung, Winson Y.; Bu, Jingyu; Jess, Ed; Kerba, Marc

doi:10.1016/j.jpainsymman.2019.12.367

Cited by 5 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20,21 Self-reported survey data from cancer centers across North America suggest that at least 20% of patients are using cannabis with therapeutic intent. 2,[22][23][24] Despite this, most health care professionals, even in the oncology setting, are ill-prepared to respond to patient requests. 17,25,26 Only 16.5% of oncology health care providers (oncologists, oncology nurses and pharmacists, and radiation technicians) in Calgary, Canada, felt sufficiently knowledgeable to confidently make recommendations regarding MC, yet the majority (69%) stated their patients disclosed using cannabis in the last month.…”

Section: Description and Disposition Of Patients With Cancer Accessin...mentioning

confidence: 99%

See 1 more Smart Citation

Description and Disposition of Patients With Cancer Accessing a Novel, Pharmacist-Led Cannabis Consultation Service

Marchese

Zhu

Charbonneau

et al. 2022

JCO Oncology Practice

View full text Add to dashboard Cite

PURPOSE: The Cannabis Consultation Service (CCS) is an innovative pharmacist-led resource at the Sunnybrook Odette Cancer Centre. Its mandate is to provide education and guide patients through access and appropriate use of high-quality plant-derived cannabinoids (PDCs). Our objective was to describe the CCS, explain its processes, and characterize patient disposition with respect to use of PDCs. METHODS: We retrospectively reviewed the charts of patients referred to the CCS from July 13, 2020, to March 05, 2021. We used descriptive statistics to report on the patient population and service metrics. RESULTS: During the 34-week period, 96 patients accessed the CCS (median age, 61 years). The top reasons for CCS consultation were management of cancer pain, insomnia, and general interest. Medical cannabis was supported as an option in 44/96 patients. Reasons for not supporting PDC use included lack of indication, potential drug interaction/contraindication, or requiring treatment with first-line therapy. Of the 40 patients requiring a medical document, 22 initiated therapy. The most common product used was a 2:50 THC:CBD (Tetrahydrocannabinol:Cannabidiol) cannabis oil. At the date of last contact, few patients remained on therapy because of lack of benefit, patient choice, and/or hesitancy. CONCLUSION: Despite patients with cancer having interest in seeking PDCs for symptom management, only a few initiated and continued therapy. Pharmacists have an opportunity to advise patients and the oncology team on the risks and benefits of PDCs. These results can be used to support the development of medical cannabis programs by oncology centers and focus future research priorities.

show abstract

Section: Description and Disposition Of Patients With Cancer Accessin...mentioning

confidence: 99%

“…20,21 Self-reported survey data from cancer centers across North America suggest that at least 20% of patients are using cannabis with therapeutic intent. 2,22-24…”

Section: Introductionmentioning

confidence: 99%

Description and Disposition of Patients With Cancer Accessing a Novel, Pharmacist-Led Cannabis Consultation Service

Marchese

Zhu

Charbonneau

et al. 2022

JCO Oncology Practice

View full text Add to dashboard Cite

show abstract

“…There was insufficient evidence to support cannabis use for cancer related cachexia and anorexia [20]. Karim et al found that authorizations for cannabis use in Canada between 2014 and 2016 in people with a cancer diagnosis were associated with younger age, active cancer treatment and more serious illness [21].…”

Section: Supplementsmentioning

confidence: 99%

Addressing Symptom Clusters with Complementary and Integrative Health Therapies in Palliative Care Populations: A Narrative Review

Marchand¹,

Lewin²,

Kozak³

2021

OBM ICM

View full text Add to dashboard Cite

Both palliative care (PC) and integrative medicine (IM) focus on the whole person to optimize wellbeing. Integrative palliative care combines the best of both approaches in relieving the distressing symptoms of serious illness and its treatment by combining evidence informed, pharmacological and nonpharmacological modalities that are aligned with the person’s goals, values and preferences. Healing is valued, as well as symptom relief, shared decisionmaking, person empowerment, compassionate care, and nurturing of hope. Increasingly, symptom clusters in serious illness are being recognized and addressed in both PC and IM. Symptom clusters arise from the complexity of the physical, psychological, social and spiritual aspects of a person interacting with serious illness. Many complementary and integrative health (CIH) modalities address symptom clusters effectively, and may allow for reduced doses of medication and their resulting side effects, or help alleviate the need for medication altogether, and increase health, healing and well being. Research reveals that the public desires more access to CIH including palliative care settings although actual delivery of these services in health care settings remains limited. This review explores the evidence for a combined palliative care and integrative medicine approach to symptom clusters experienced by people with serious illness through increased access and funding of these services in the community and health care settings with quality practitioners.

show abstract

Cannabis use among Danish patients with cancer: a cross-sectional survey of sociodemographic traits, quality of life, and patient experiences

Nielsen

Ruhlmann

Eckhoff

et al. 2021

Support Care Cancer

View full text Add to dashboard Cite

Medical Cannabis Authorization in Patients With Cancer in the Prelegalization Era: A Population-Based Study

Cited by 5 publications

References 15 publications

Description and Disposition of Patients With Cancer Accessing a Novel, Pharmacist-Led Cannabis Consultation Service

Description and Disposition of Patients With Cancer Accessing a Novel, Pharmacist-Led Cannabis Consultation Service

Addressing Symptom Clusters with Complementary and Integrative Health Therapies in Palliative Care Populations: A Narrative Review

Cannabis use among Danish patients with cancer: a cross-sectional survey of sociodemographic traits, quality of life, and patient experiences

Contact Info

Product

Resources

About